Healthcare Services

Neuropathic Pain Market Revenue Growth Expected to Reach $8.47 Billion by 2030 with 8.1% CAGR

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Neuropathic Pain Market Projected To Become By 2030 Based On Its 2026 Valuation?

The neuropathic pain market has seen significant expansion over recent years. Projections indicate its value will increase from $5.78 billion in 2025 to $6.2 billion by 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical growth is attributable to factors such as the increasing incidence of diabetes, the widespread adoption of antidepressants and anticonvulsants, heightened awareness concerning neuropathic pain conditions, the evolution of opioid-based treatments, and the initial integration of imaging for diagnostic purposes.

The neuropathic pain market size is projected for substantial expansion over the coming years, reaching $8.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This expansion during the forecast period is fueled by a burgeoning shift towards non-opioid treatments, an escalating demand for personalized pain management strategies, the broadening application of complementary therapies, increased funding in diagnostic innovations, and the creation of sophisticated multimodal treatment options. Key trends anticipated in this period encompass the growing embrace of multimodal therapy approaches, a heightened need for non-opioid solutions for pain, the increasing incorporation of physical and psychological therapies, advancements in early diagnosis facilitated by imaging techniques, and a sharpened focus on addressing diabetic neuropathy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp

Which Market Drivers Are Supporting The Expansion Of The Neuropathic Pain Market?

The increasing occurrence of chronic pain is anticipated to stimulate the expansion of the neuropathic pain market in the future. Chronic pain, characterized as discomfort enduring for at least three months, impacts a considerable segment of the population and substantially diminishes their quality of life. The rise in chronic pain instances stems from factors including aging demographics, nerve injury, and long-term conditions such as diabetes. Therapies for neuropathic pain contribute to public health by addressing nerve malfunctions, alleviating symptoms, and enhancing patients’ everyday activities. For example, data released by the Centers for Disease Control and Prevention (CDC), a US-based nation’s health protection agency, in November 2024, indicated that adult populations in 2023 faced a 24.3% prevalence of chronic pain and an 8.5% prevalence of high-impact chronic pain, which is equivalent to 34.9% among those suffering from chronic pain, with women, American Indian and Alaska Native adults, and individuals aged 65 years and older exhibiting particularly elevated rates. Consequently, the growing incidence of chronic pain is fueling the neuropathic pain market.

What Segment Groups Are Identified Within The Neuropathic Pain Market?

The neuropathic pain market covered in this report is segmented –

1) By Treatment: Medications, Multimodal Therapy

2) By Diagnosis: Imaging, Blood Tests And Physical Examination

3) By Indication: Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications

4) By End User: Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Medications: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

2) By Multimodal Therapy: Combination Of Medications, Physical Therapy, Psychological Therapy, Lifestyle Modifications, Complementary Therapies

What Trends Are Affecting The Expansion Of The Neuropathic Pain Market?

Leading companies in the neuropathic pain market are integrating artificial intelligence technologies for enhanced diagnosis, personalized treatment strategies, continuous monitoring, drug discovery, and data-driven insights to improve patient outcomes and refine pain management approaches. For instance, in March 2023, Nevro Corp., a US-based medical device company, introduced the Senza HFX iQ spinal cord stimulation (SCS) system. This innovative technology leverages artificial intelligence (AI) to customize pain relief for individual patients. The system, which includes the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, is engineered to address non-surgical back pain and painful diabetic neuropathy by adapting to patient responses and feedback. It utilizes a distinctive algorithm developed from extensive patient data and allows patients to modify their pain relief program using a smartphone app. The system’s digital ecosystem facilitates data collection and potential updates. This technology aims to elevate pain relief through consistency and personalization, signifying a notable advancement in SCS therapy.

Which Companies Hold Significant Positions In The Neuropathic Pain Market?

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol‑Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., Nevro Corp., InvaGen Pharmaceuticals Inc, Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Assertio Therapeutics Inc, NeuroMetrix Inc, OMRON Healthcare Co Ltd

Read the full neuropathic pain market report here:

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

How Is The Neuropathic Pain Market Distributed Across Key Geographic Regions?

North America was the largest region in the neuropathic pain market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuropathic pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neuropathic Pain Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12922&type=smp

Browse Through More Reports Similar to the Global Neuropathic Pain Market 2026, By The Business Research Company

Optic Atrophy Management Global Market Report

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Peripheral Neuropathy Global Market Report

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Retinal Disorder Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795